Find My Journal

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Hossein Borghaei, Corey J. Langer, Shirish M. Gadgeel, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Sanatan Saraf, Steven M. Keller, Leena Gandhi

Journal of Thoracic Oncology, 2018

Fox Chase Cancer Center, University of Pennsylvania, Wayne State University, The Barbara Ann Karmanos Cancer Institute, The University of Texas MD Anderson Cancer Center, South Texas Accelerated Research Therapeutics, Sanford Health, University of Virginia, University of Washington, Cleveland Clinic, Indiana University School of Medicine, Indiana University – Purdue University Indianapolis, Fargo VA Health Care System, National Taiwan University Hospital, University of California, San Francisco, Massachusetts General Hospital, Dana-Farber Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), NYU Langone Health

Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

195

Citations

View on Google Scholar